Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
PDF (126K)
Journal: 2002/May - Journal of Medical Genetics
ISSN: 1468-6244
PUBMED: 12011145
Abstract:
BACKGROUND
Cross sectional studies have shown that 1-2% of patients with neurofibromatosis 1 (NF1) develop malignant peripheral nerve sheath tumours (MPNST). However, no population based longitudinal studies have assessed lifetime risk.
METHODS
NF1 patients with MPNST were ascertained from two sources for our north west England population of 4.1 million in the 13 year period 1984-1996: the North West Regional NF1 Register and review of notes of patients with MPNST in the North West Regional Cancer Registry.
RESULTS
Twenty-one NF1 patients developed MPNST, equivalent to an annual incidence of 1.6 per 1000 and a lifetime risk of 8-13%. There were 37 patients with sporadic MPNST. The median age at diagnosis of MPNST in NF1 patients was 26 years, compared to 62 years in patients with sporadic MPNST (p<0.001). In Kaplan-Meier analyses, the five year survival from diagnosis was 21% for NF1 patients with MPNST, compared to 42% for sporadic cases of MPNST (p=0.09). One NF1 patient developed two separate MPNST in the radiation field of a previous optic glioma.
CONCLUSIONS
The lifetime risk of MPNST in NF1 is much higher than previously estimated and warrants careful surveillance and a low threshold for investigation.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(248)
References
(18)
Clinical trials
(2)
Diseases
(1)
Organisms
(1)
Similar articles
Articles by the same authors
Discussion board
J Med Genet 39(5): 311-314
PMID: 12011145

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

Abstract

Background: Cross sectional studies have shown that 1-2% of patients with neurofibromatosis 1 (NF1) develop malignant peripheral nerve sheath tumours (MPNST). However, no population based longitudinal studies have assessed lifetime risk.

Methods: NF1 patients with MPNST were ascertained from two sources for our north west England population of 4.1 million in the 13 year period 1984-1996: the North West Regional NF1 Register and review of notes of patients with MPNST in the North West Regional Cancer Registry.

Results: Twenty-one NF1 patients developed MPNST, equivalent to an annual incidence of 1.6 per 1000 and a lifetime risk of 8-13%. There were 37 patients with sporadic MPNST. The median age at diagnosis of MPNST in NF1 patients was 26 years, compared to 62 years in patients with sporadic MPNST (p<0.001). In Kaplan-Meier analyses, the five year survival from diagnosis was 21% for NF1 patients with MPNST, compared to 42% for sporadic cases of MPNST (p=0.09). One NF1 patient developed two separate MPNST in the radiation field of a previous optic glioma.

Conclusion: The lifetime risk of MPNST in NF1 is much higher than previously estimated and warrants careful surveillance and a low threshold for investigation.

Full Text

The Full Text of this article is available as a PDF (126K).

Supplementary Material

[Authors' Correction]

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989 Nov;26(11):704–711.[PMC free article] [PubMed] [Google Scholar]
  • Sørensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986 Apr 17;314(16):1010–1015. [PubMed] [Google Scholar]
  • King AA, Debaun MR, Riccardi VM, Gutmann DH. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000 Aug 28;93(5):388–392. [PubMed] [Google Scholar]
  • Poyhonen M, Niemela S, Herva R. Risk of malignancy and death in neurofibromatosis. Arch Pathol Lab Med. 1997 Feb;121(2):139–143. [PubMed] [Google Scholar]
  • Harris M, Hartley AL, Blair V, Birch JM, Banerjee SS, Freemont AJ, McClure J, McWilliam LJ. Sarcomas in north west England: I. Histopathological peer review. Br J Cancer. 1991 Aug;64(2):315–320.[PMC free article] [PubMed] [Google Scholar]
  • D'AGOSTINO AN, SOULE EH, MILLER RH. PRIMARY MALIGNANT NEOPLASMS OF NERVES (MALIGNANT NEURILEMOMAS) IN PATIENTS WITHOUT MANIFESTATIONS OF MULTIPLE NEUROFIBROMATOSIS (VON RECKLINGHAUSEN'S DISEASE). Cancer. 1963 Aug;16:1003–1014. [PubMed] [Google Scholar]
  • Greager JA, Reichard KW, Campana JP, DasGupta TK. Malignant schwannoma of the head and neck. Am J Surg. 1992 Apr;163(4):440–442. [PubMed] [Google Scholar]
  • Gardner RJ, Mungall AJ, Dunham I, Barber JC, Shield JP, Temple IK, Robinson DO. Localisation of a gene for transient neonatal diabetes mellitus to an 18.72 cR3000 (approximately 5.4 Mb) interval on chromosome 6q. J Med Genet. 1999 Mar;36(3):192–196.[PMC free article] [PubMed] [Google Scholar]
  • Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet. 1989 Nov;26(11):712–721.[PMC free article] [PubMed] [Google Scholar]
  • Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986 May 15;57(10):2006–2021. [PubMed] [Google Scholar]
  • Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer. 1993 Feb 15;71(4):1247–1253. [PubMed] [Google Scholar]
  • Doorn PF, Molenaar WM, Buter J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol. 1995 Feb;21(1):78–82. [PubMed] [Google Scholar]
  • Das Gupta TK, Brasfield RD. Solitary malignant schwannoma. Ann Surg. 1970 Mar;171(3):419–428.[PMC free article] [PubMed] [Google Scholar]
  • Ghosh BC, Ghosh L, Huvos AG, Fortner JG. Malignant schwannoma. A clinicopathologic study. Cancer. 1973 Jan;31(1):184–190. [PubMed] [Google Scholar]
  • Loree TR, North JH, Jr, Werness BA, Nangia R, Mullins AP, Hicks WL., Jr Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors. Otolaryngol Head Neck Surg. 2000 May;122(5):667–672. [PubMed] [Google Scholar]
  • Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989 May;114(5):788–792. [PubMed] [Google Scholar]
  • Hoyt WF, Baghdassarian SA. Optic glioma of childhood. Natural history and rationale for conservative management. Br J Ophthalmol. 1969 Dec;53(12):793–798.[PMC free article] [PubMed] [Google Scholar]
  • Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, Bingham J. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353–357.[PMC free article] [PubMed] [Google Scholar]
University Department of Medical Genetics, St Mary's Hospital, Manchester M13 0JH, UK. ku.shn.tsewn.thmc.lartnec@snaveG
University Department of Medical Genetics, St Mary's Hospital, Manchester M13 0JH, UK. ku.shn.tsewn.thmc.lartnec@snaveG
Copyright notice

Abstract

Background: Cross sectional studies have shown that 1-2% of patients with neurofibromatosis 1 (NF1) develop malignant peripheral nerve sheath tumours (MPNST). However, no population based longitudinal studies have assessed lifetime risk.

Methods: NF1 patients with MPNST were ascertained from two sources for our north west England population of 4.1 million in the 13 year period 1984-1996: the North West Regional NF1 Register and review of notes of patients with MPNST in the North West Regional Cancer Registry.

Results: Twenty-one NF1 patients developed MPNST, equivalent to an annual incidence of 1.6 per 1000 and a lifetime risk of 8-13%. There were 37 patients with sporadic MPNST. The median age at diagnosis of MPNST in NF1 patients was 26 years, compared to 62 years in patients with sporadic MPNST (p<0.001). In Kaplan-Meier analyses, the five year survival from diagnosis was 21% for NF1 patients with MPNST, compared to 42% for sporadic cases of MPNST (p=0.09). One NF1 patient developed two separate MPNST in the radiation field of a previous optic glioma.

Conclusion: The lifetime risk of MPNST in NF1 is much higher than previously estimated and warrants careful surveillance and a low threshold for investigation.

Abstract
Full Text
Click here to view.
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.